Observational study of Philadelphia-positive ALL treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows adults with Philadelphia chromosome-positive ALL who are receiving a combination of targeted therapy (a BCR::ABL1 inhibitor) and other treatments. It collects real-world data to better understand how these treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have Philadelphia chromosome-positive ALL (a specific type of leukemia)
- You have already been treated with a BCR::ABL1 inhibitor (a targeted pill) combined with chemotherapy, steroids, or a monoclonal antibody
- You are not enrolled in any other clinical trial
- You have not previously refused to allow your medical data to be used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
This study follows children and teens with newly diagnosed certain leukemia (ALL) and certain favorable brain tumors to learn best care and outcomes. It may help your team compare standard treatments and monitor health over time.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.